These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8437630)

  • 1. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 2. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on monoclonal antibody therapy in the gram-negative sepsis syndrome.
    Hecker RB
    J Am Osteopath Assoc; 1992 Aug; 92(8):1017-20. PubMed ID: 1429060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal antibodies in sepsis.
    de Koning J; Westendorp RG
    Neth J Med; 1992 Apr; 40(3-4):215. PubMed ID: 1603215
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody to endotoxin in the treatment of gram-negative sepsis.
    McCabe WR
    JAMA; 1992 May; 267(17):2325; author reply 2326. PubMed ID: 1564763
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody to endotoxin in the treatment of gram-negative sepsis.
    van Deventer S
    JAMA; 1992 May; 267(17):2325-6. PubMed ID: 1564765
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-endotoxin monoclonal antibodies.
    Warren HS; Danner RL; Munford RS
    N Engl J Med; 1992 Apr; 326(17):1153-7. PubMed ID: 1552919
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antiendotoxin agent HA-1A (Centoxin).
    Inglis TJ; Hawkey PM; Lacey RW; Bodeham A; Kay E; Calvert RT
    Lancet; 1993 Jan; 341(8840):303. PubMed ID: 8093933
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
    Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
    J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.